# A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

> **NCT07546500** · PHASE3 · NOT_YET_RECRUITING · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 420 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Investigator's choice of Chemotherapy
- **DRUG:** Azenosertib

## Key facts

- **NCT ID:** NCT07546500
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2028-05-31
- **Final completion:** 2030-04-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07546500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07546500, "A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07546500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*